Kornimate/medical-research-clean huggingface dataset:
effectiveness of female community health volunteers training on hypertension knowledge and blood pressure measurement skills in nepal

Conditions: Female Community Health Volunteers

Summary: the investigators aimed to investigate the effectiveness of training fchvs in hypertension knowledge and blood pressure measuring skills and explore their perceptions of challenges and opportunities to deliver hypertension counseling and monitor blood pressure in the community. the investigators conducted a quasi-experimental study design among 131 fchvs from namobuddha and mandandeupur municipalities. the investigators quantitatively measured the baseline and end-line hypertension knowledge and bp measurement skills after providing a one-day training on hypertension knowledge and bp measurement. furthermore, the investigators conducted three focus group discussions with fchvs to explore the challenges and opportunities of fchvs in community-based hypertension management.

female community health volunteers (fchvs) in nepal could play a role in preventing and managing hypertension. limited studies have been conducted on nepal's fchv knowledge and capacity to deliver hypertension-related counseling and services. the investigators investigate the effectiveness of training fchvs in hypertension knowledge and blood pressure measuring skills and explore their perceptions of challenges and opportunities to deliver hypertension counseling and monitor blood pressure in the community. the investigators conducted a quasi-experimental study design among 131 fchvs from namobuddha and mandandeupur municipalities. the investigators quantitatively measured the baseline and end-line hypertension knowledge and bp measurement skills after providing a one-day training on hypertension knowledge and bp measurement. the investigators used the hypertension knowledge level scale (hk-ls) to assess the knowledge through face-to-face interviews and observed bp measurement skills using an observation checklist. the investigators used paired t-tests to see the mean difference before and after the training. the investigators performed linear regression to assess the hypertension knowledge and bp measurement skills scores with socio-demographic and fchv's general performance. furthermore, the investigators conducted three focus group discussions with fchvs to explore the challenges and opportunities of fchvs in community-based hypertension management. the investigators transcribed the recorded discussion verbatim and analyzed it using the framework analysis method

Eligibility criteria:
inclusion criteria: * appointed as fchv * age 18 years and older exclusion criteria: * not able to respond during the data collection period * out of municipality during the data collection period

Keywords: effectiveness training hypertension knowledge blood pressure measurement skills
effect of aerobic interval training with vitamin d supplement on functional capacity and perceived myalgia

Conditions: Vitamin D Deficiency

Summary: this study aimed to investigate whether there will be an effect of adding a program of aerobic interval training in managing patients suffering from myalgia associated with vitamin d deficiency.

forty five women complaining from myalgia with vitamin d deficiency participating in this study. their ages are ranged from 30 to 40 years. they are assigned randomly into three groups: * group (a): included 15 patients who are participating in an aerobic interval training exercise program with vitamin d supplementation (cholecalciferol 400 iu/day). * group (b): included 15 patients who are receiving vitamin d supplementation only (cholecalciferol 400 iu/day). * group (c): included 15 patients who are participating in an interval training exercise program only. the intervention will last for 12 weeks

Eligibility criteria:
inclusion criteria: * forty five sedentry women with non specific myalgia pain. * the patients' ages ranged from 30 -40 years. * all patients have non specific muscle pain for more than 2 months. * they have vitamin d deficiency. * all patients have bmi from 25 to 34.9 kg/m2. * all patients were clinically and medically stable when attending the study. exclusion criteria: * unstable cardiovascular and chest problems. * patients with diseases which affect vitamin d level as a history of rheumatic or metabolic bone diseases and diabetes. * patients taking drugs which affect vitamin d level as steroids and anticonvulsants drugs . * musculoskeletal disorders which may affect their physical ability to do the exercises.
expanded access protocol for cemiplimab in metastatic or locally advanced cutaneous squamous cell carcinoma

Conditions: Cutaneous Squamous Cell Carcinoma

Summary: the objective of this program is to provide access to cemiplimab (regn2810) to patients with metastatic cutaneous squamous cell carcinoma (mcscc) or locally advanced cutaneous squamous cell carcinoma (lacscc) who are not candidates for surgery prior to cemiplimab (regn2810) being commercially available.


Eligibility criteria:
key inclusion criteria: 1. histologically confirmed diagnosis of invasive cutaneous squamous cell carcinoma (cscc) 2. hepatic function: 1. total bilirubin ≤1.5 x upper limit of normal (uln; if liver metastases ≤3 x uln). 2. transaminases ≤3 x uln (or ≤5.0 x uln, if liver metastases) 3. alkaline phosphatase ≤2.5 x uln (or ≤5.0 x uln, if liver or bone metastases) patients with hepatic metastases: if transaminase levels (ast and/or alt) are \>3 x but ≤5 x uln, total bilirubin must be ≤1.5 x uln. if total bilirubin is \>1.5 x but ≤3 x uln, both transaminases (ast and alt) must be ≤3 x uln 3. renal function: serum creatinine ≤1.5 x uln or estimated creatinine clearance (crcl) \>30 ml/min 4. bone marrow function: 1. hemoglobin ≥9.0 g/dl 2. absolute neutrophil count (anc) ≥1.5 x 10\^9/l 3. platelet count ≥75 x 10\^9/l 5. patients not candidates for surgery include the examples below, but are not limited to: * metastatic disease (distant or nodal) * recurrence in the same location and curative resection is unlikely * significant local invasion that precludes complete resection * surgery may result in severe disfiguration or dysfunction * other conditions deemed to be contraindicating for surgery key exclusion criteria: 1. ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (iraes). the following are not exclusionary: vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment 2. prior treatment with other immune modulating agents that was (a) within fewer than 4 weeks (28 days) prior to the first dose of cemiplimab (regn2810), or (b) associated with immune-mediated adverse events (aes) that were ≥ grade 1 within 90 days prior to the first dose of cemiplimab (regn2810), or (c) associated with toxicity that resulted in discontinuation of the immune-modulating agent 3. continuous immunosuppressive corticosteroid treatment (doses \>10 mg prednisone daily or equivalent) within 2 weeks prior to the first dose of cemiplimab (regn2810)note: patients who require brief course of steroids (eg, as prophylaxis for imaging studies) are not excluded 4. active uncontrolled infection requiring therapy, including infection with human immunodeficiency virus, or active infection with hepatitis b virus (hbv) or hepatitis c virus (hcv) 5. history of pneumonitis within the last 5 years note: other protocol defined inclusion/exclusion criteria may apply
study of ec0489 for the treatment of refractory or metastatic tumors

Conditions: Cancer

Summary: this is a phase 1 clinical trial evaluating the safety and tolerability of escalating doses of ec0489 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.

this is a phase 1, dose escalation study of ec0489 administered by intravenous bolus (iv) during weeks 1 and 3 of a 4-week cycle in part a and weekly on a 4-week cycle in part b. both parts are open to patients with refractory or metastatic cancer who have exhausted standard therapeutic options. ec0489 is a drug that is specifically designed to enter cells via a folate vitamin receptor. experimental evidence shows that the target receptor is over-expressed in many human cancers. there are no previous human studies of ec0489; however, lab research (research in test tubes or animals) using ec0489 has shown activity against tumors in animals. this activity in animal models suggests that ec0489 may be useful as chemotherapy against human cancers. the primary objective of this study is to determine the safety and maximum tolerated dose of ec0489 given by intravenous bolus. the efficacy of treatment will also be measured.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * histological or cytological diagnosis of neoplasm * no effective standard therapeutic options * ecog performance status of 0-2 * ≥ 4 weeks post therapeutic radiation or recovered (or returned to baseline) from any acute toxicity associated with prior cytotoxic therapy. patients previously treated with non-cytotoxic therapy (e.g., egfr, vgef, etc.) and who have recovered from or have controlled drug-associated toxicity are allowed to enter the trial after a period consisting of 4 half-lives of the agent. * negative serum pregnancy test for women of child-bearing potential within one week prior to treatment with investigational agents (99mtc-ec20 and ec0489)and willingness to practice contraceptive methods * adequate bone marrow reserve, renal and hepatic function exclusion criteria: * concurrent malignancies * women who are pregnant or breast-feeding * evidence of symptomatic brain metastases * receiving concomitant anticancer therapy (excluding supportive care) * requires palliative radiotherapy at time of study entry * requires antifolate therapy for comorbid conditions * heart failure characterized as greater than nyha class i * history of myocardial infarct * any of the following baseline echocardiogram findings: valvular lesions (stenosis or insufficiency) characterized as greater than moderate, systolic ventricular impairment characterized as greater than mild, left ventricular ejection fraction \< 55%, any feature of the echocardiogram that would confound interpretation of the serial echocardiograms required by the protocol

Keywords: cancer phase 1 ec0489 ec20 refractory metastatic experimental
open sinus lift technique with simultaneous implantation using platelet rich fibrin (prf) versus nano-crystalline hydroxyapatite

Conditions: Atrophied Posterior Maxillary Ridge

Summary: evaluation of bone quantity in open sinus lift technique with space maintaining using platelet rich fibrin (prf) as sole augmentation material versus nano crystalline hydroxyapatite with simultaneous placing of implants.

evaluation of bone quantity in open sinus lift technique with simultaneous implantation using platelet rich fibrin (prf) versus nano-crystalline hydroxyapatite as sole grafting material in patients with atrophied posterior maxillary ridge which provides a new modality for treatment of patients with atrophied posterior maxillary ridge with least cost and a much easier way using platelet rich fibrin (prf) as substitution to bone graft

Eligibility criteria:
inclusion criteria: * all patients should be seeking for implant supported prosthesis in posterior maxilla bilaterally * all patients should have atrophied posterior maxillary ridge with the maximum height of the alveolar bone is from 3 mm to 5 mm exclusion criteria: * ongoing steroid therapy; * uncontrolled diabetes; * recent cardiovascular diseases; * inflammation of the maxillary sinus; * previous radiant therapy for neoplastic pathologies * patient who have had previous failed sinus augmentation, or exhibited pathological finding or had a history of maxillary sinus disease or operations or whose medical condition might increase surgical risk of the research protocol were excluded.

Keywords: simultaneous implantation dental implant open sinus lifting prf platelet rich fibrin (prf)
cost-effectiveness and patients satisfaction of conventional vs robotic-assisted laparoscopy in gynecologic oncologic indications

Conditions: UTERINE CERVICAL NEOPLASMS; ENDOMETRIAL NEOPLASMS

Summary: laparoscopic surgery is gaining currency in the field of oncologic care, particularly for colorectal and gynecologic cancers. this innovation could be used either for staging purpose and therefore could steer global therapeutic options or for surgical management only. increase knowledge and skills lead to an increase in the number and rate of the women this innovation could be offered. the project team observed a shift from traditional surgical management (abdominal radical surgery) towards laparoscopic with a focus on lymphadenectomy. this innovation however increases some costs (the surgical stage) but decrease some others (the post surgical stage). foreseeing the pace of the dissemination needs to have objective and reliable data about who had access to laparoscopic surgery and who didn't (and why) and accurate assessment of related costs. this program will focus on uterine cancer (both cervix and corpus).


Eligibility criteria:
inclusion criteria: * age\>18 years * endometrial or cervical cancer exclusion criteria: -

Keywords: laparoscopic surgery uterine neoplasms
prevalence of sexually transmitted infections among people attending the sexual assault centre in oslo, norway.

Conditions: Sexual Assault and Rape; Sexually Transmitted Diseases

Summary: in this study the investigators seek to register the prevalence of sexually transmitted infections (sti) among people attending the sexual assault centre in oslo, norway. the main aim of this study is to gather representative data on stis after sexual assaults. consequently, if the attendance for medical follow up turns out to be good/sufficient, prophylactic (antibiotic) treatment can potentially be omitted.

patients who attend sexual assault centres are often concerned about being infected with stis. therefore, the patients attending sexual assault centres are offered examination and often receive prophylactic treatment against some stis (e.g. chlamydia trachomatis, hiv and hepatitis b). in this study, the investigators seek to register the prevalence of sti among people attending the sexual assault centre in oslo, norway. the primary aim of the study is to gather representative data on stis after a sexual assault. furthermore, the investigators want to evaluate if there are any variables that can predict transmission after a sexual assult. results from this study will also be compared with findings of sti in the general population. at the sexual assault centre in oslo, norway, patients are routinely offered three medical follow up consultations. consequently, if the attendance at follow up visits turns out to be adequate, prophylactic (antibiotic) treatment can potentially be omitted. since victims of assault are in a vulnerable situation, it would be useful to be able to inform them more precisely about infection risk and provide adequate prophylactic treatment. more knowledge about the incidence of infection after abuse will increase patient safety and improve the quality of treatment for these patients.

Eligibility criteria:
inclusion criteria: * patients attending and examined after sexual assault at the sexual assault centre in oslo (at oslo accident and emergency outpatient clinic). * written informed consent exclusion criteria: * patients who only had a consultation only with a social worker and no medical examination. * unable to communicate in norwegian, swedish, danish or english language

Keywords: sexual assault sexually transmitted diseases chlamydia trachomatis mycoplasma genitalium neisseria gonorrhoeae hepatitis b and c hiv syphilis follow up visits after sexual assault
serious game interventions to reduce viral hepatitis c among plwh-msm

Conditions: Viral Hepatitis C

Summary: the study is aimed to provide high-risk, hiv-infection, men who have sex with men (msm) with healthcare education regarding viral hepatitis c, through either serious game intervention or traditional online health education. after the education, each participants will be followed for 48 weeks and the change of risky sexual behaviors, acquisition of hcv and other stis will be followed during the study periods.

high-risk msm living with hiv were participated in our study will be assigned (by randomization) to either: 1. serious game intervention: 1 single session of serious game for the participants to play (estimation to take 25-40 minutes). hepatitis c virus (hcv)-related healthcare informations, including the severity of illness, route of transmission, preventive strategies and treatment options, would be embedded in the game. 2. traditional online health education (reading materials): 1 single session of healthcare education regarding hcv (with similar contents) will be provided. after the healthcare intervention, each participants will be followed for 48 weeks. assessment of risky sexual practice (by questionnaire), test of plasma hcv rna and serological test of syphilis (optional), and detection of sexually-transmitted bacterial pathogens (optional) will be performed at the enrollment and then every 12 weeks during the observation.

Eligibility criteria:
inclusion criteria: * high-risk msm living with hiv, defined as: 1. had prior hcv infection, and had cleared hcv through treatment or spontaneously 2. had any sti within the past 12 months 3. had any unexplained elevation of liver transaminase in the past 6 months 4. had at least 1 unprotected anal sex during the past 6 months * being able to use mobile smartphone and understand study materials * repeat entry of study is permitted, but the interval between health education intervention should \>52 weeks. exclusion criteria: * hcv rna positive and yet clear virus (nor reaching svr12). * admission for any acute illness (including aids-defining conditions)

Keywords: serious game viral hepatitis c sexually-transmitted infections health belief model harm reduction sexualized drugs behavioral interventions
phase 3 safety study for the treatment of presbyopia subjects

Conditions: Presbyopia; Near Vision; Miosis; Eye Diseases

Summary: safety study of the long-term safety of lnz101 in presbyopic subjects

safety study: multi-center, double-masked phase 3 evaluation of the long-term safety of lnz101 in presbyopic subjects

Eligibility criteria:
inclusion criteria: 1. be able and willing to provide written informed consent and sign a health information portability and accountability act (hipaa) form prior to any study procedure being performed; 2. be able and willing to follow all instructions and attend all study visits; 3. be 45-75 years of age of either sex and any race or ethnicity at visit 1; 4. be presbyopic in both eyes as determined by manifest refraction documented at visit 1; 5. have +1.00 to -4.00 diopter(d) of sphere calculated in minus cylinder (up to 2.00d of cylinder) in both eyes determined by manifest refraction documented at visit 1 exclusion criteria: 1. be a female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy; 2. have known contraindications or sensitivity to the use of any of the study medications or their components; 3. have an active ocular infection at visit 1 (bacterial, viral, or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation in either eye; 4. have moderate or severe dry eye defined as total corneal fluorescein staining at visit 1; 5. have clinically significant abnormal lens findings during dilated slit-lamp biomicroscopy and fundus exam at visit 1

Keywords: pharmaceutical solutions opthalmic solutions eye drops clarity presbyopia miotic
safety and tolerability of initiating lcz696 in heart failure patients

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: the purpose of this study is to assess the safety and tolerability of initiating lcz696 in heart failure patients with reduced ejection fraction (hf-ref) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; chf with new york heart association class ii-iv; left ventricular ejection fraction ≤ 35%; on beta blockers exclusion criteria: * potassium \> 5.2 mmol/l; estimated glomerular filtration rate \ 180 mmhg; history of intolerance to recommended target doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers other protocol-defined inclusion/exclusion criteria may apply.

Keywords: heart failure, reduced ejection fraction, lcz696, titration, safety, tolerability
quality of life analysis of arimidex treatment in postmenopausal patients with breast cancer

Conditions: Breast Cancer

Summary: this is an open label, non-interventional quality of life analysis for arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire


Eligibility criteria:
inclusion criteria: * provision of informed consent * postmenopausal, hormon receptor positive patients with early breast cancer treated with arimidex * investigators are requested to recruit patients only with at least 1 month prior arimidex treatment. exclusion criteria: * allergy to substance of medication * pre-perimenopausal woman * woman not eligible for treatment

Keywords: quality of life
risk stratification-directed therapy for aml with t(8;21) /aml1-eto+

Conditions: Acute Myeloid Leukemia; Risk Stratification

Summary: acute myeloid leukemia with t(8;21) /aml1-eto-positive (ae aml) is a heterogeneous disease entailing different prognoses. there were significant differences in the therapeutic effect between different subgroups of ae aml. therefore, risk stratification-directed therapy is very necessary for ae aml.

acute myeloid leukemia with t(8;21) /aml1-eto-positive (ae aml) is a heterogeneous disease entailing different prognoses.there were significant differences in the therapeutic effect between different subgroups of ae aml. for example, patients with c-kit mutation had higher relapse rate and lower overall survival, compared with those without c-kit mutation. therefore, risk stratification-directed therapy is very necessary for ae aml. the purpose of this study is to establish risk stratification-directed therapy for ae aml.

Eligibility criteria:
inclusion criteria: * ae aml aged 14-70 * no abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * expected survival time is more than 2 months exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)